548 related articles for article (PubMed ID: 18309461)
1. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
[TBL] [Abstract][Full Text] [Related]
2. ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A-B-C ? : editorial to: effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.
de Boer RA; van Veldhuisen DJ
Cardiovasc Drugs Ther; 2008 Aug; 22(4):261-3. PubMed ID: 18418705
[No Abstract] [Full Text] [Related]
3. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN).
Remme WJ; Riegger G; Hildebrandt P; Komajda M; Jaarsma W; Bobbio M; Soler-Soler J; Scherhag A; Lutiger B; Rydén L
Cardiovasc Drugs Ther; 2004 Jan; 18(1):57-66. PubMed ID: 15115904
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
Hartmann F; Packer M; Coats AJ; Fowler MB; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Anker SD; Amann-Zalan I; Hoersch S; Katus HA
Circulation; 2004 Sep; 110(13):1780-6. PubMed ID: 15381643
[TBL] [Abstract][Full Text] [Related]
6. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Bhardwaj A; Rehman SU; Mohammed AA; Gaggin HK; Barajas L; Barajas J; Moore SA; Sullivan D; Januzzi JL
Am Heart J; 2012 Nov; 164(5):793-799.e1. PubMed ID: 23137512
[TBL] [Abstract][Full Text] [Related]
7. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
Gundogdu F; Bozkurt E; Kiziltunc A; Sevimli S; Arslan S; Gurlertop Y; Senocak H; Karakelleoglu S
Echocardiography; 2007 Feb; 24(2):113-7. PubMed ID: 17313541
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
[TBL] [Abstract][Full Text] [Related]
9. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
Olsson LG; Swedberg K; Cleland JG; Spark PA; Komajda M; Metra M; Torp-Pedersen C; Remme WJ; Scherhag A; Poole-Wilson P;
Eur J Heart Fail; 2007 Aug; 9(8):795-801. PubMed ID: 17693380
[TBL] [Abstract][Full Text] [Related]
10. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
Fujimura M; Akaike M; Iwase T; Yoshida S; Sumitomo Y; Yagi S; Ikeda Y; Hashizume S; Aihara K; Nishiuchi T; Yasumura Y; Matsumoto T
Acta Cardiol; 2009 Oct; 64(5):589-95. PubMed ID: 20058503
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.
Omland T; Sabatine MS; Jablonski KA; Rice MM; Hsia J; Wergeland R; Landaas S; Rouleau JL; Domanski MJ; Hall C; Pfeffer MA; Braunwald E;
J Am Coll Cardiol; 2007 Jul; 50(3):205-14. PubMed ID: 17631211
[TBL] [Abstract][Full Text] [Related]
13. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
14. Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol.
Nessler J; Nessler B; Kitliński M; Stepniewski M; Piwowarska W
Cardiol J; 2008; 15(4):329-37. PubMed ID: 18698541
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
[TBL] [Abstract][Full Text] [Related]
16. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
17. Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure.
Dini FL; Gabutti A; Passino C; Fontanive P; Emdin M; De Tommasi SM
Int J Cardiol; 2010 Apr; 140(3):344-50. PubMed ID: 19128846
[TBL] [Abstract][Full Text] [Related]
18. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
[TBL] [Abstract][Full Text] [Related]
19. Value of brain natriuretic peptides in primary care patients with the clinical diagnosis of chronic heart failure.
Zuber M; Cuculi F; Attenhofer Jost CH; Kipfer P; Buser P; Seifert B; Erne P
Scand Cardiovasc J; 2009; 43(5):324-9. PubMed ID: 19247872
[TBL] [Abstract][Full Text] [Related]
20. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis.
Savarese G; Musella F; D'Amore C; Vassallo E; Losco T; Gambardella F; Cecere M; Petraglia L; Pagano G; Fimiani L; Rengo G; Leosco D; Trimarco B; Perrone-Filardi P
JACC Heart Fail; 2014 Apr; 2(2):148-58. PubMed ID: 24720923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
